Gronghui Sept. 26 CICC released a research report saying that it was first awarded the "outperform industry" rating of China Resources Medical, with a target price of HK $6.99. According to the report, it is clearly pointed out in the 14th five-year Plan that people's demand for a high level of medical services is more urgent, and the future development of medical services will show a diversified, multi-level and multifaceted trend. China Resources Medical own hospital business reshaping, extension mergers and acquisitions to further increase the size to create a brand effect. 1) self-owned hospital: the medical business income of the company's own hospital is 6.76 billion yuan in 2022, and the CAGR from 2020 to 2022 is 30.2%. After the strategic reshaping in 2022, the company has upgraded into a "1x" model of sustainable development by focusing on the development of discipline construction. 2) extension M & A: the company adopts the mode of "M & A-integration-injection". At present, the company has accumulated rich experience in cooperation with the target projects of state-owned enterprises. In the future, the company plans to continue to find suitable targets and further enhance the synergy of resources by building a collectivized unified management model.